The Diagnostic Ability of White Light Endoscopy and Magnifying Endoscopy With Optical Enhancement System

Sponsor
Shandong University (Other)
Overall Status
Recruiting
CT.gov ID
NCT04411589
Collaborator
(none)
300
1
2
24
12.5

Study Details

Study Description

Brief Summary

The purpose of this study is to valuation of the diagnostic ability of white light imaging and magnifying endoscopy with optical enhancement system in early gastric cancer and intraepithelial neoplasia.

Condition or Disease Intervention/Treatment Phase
  • Device: magnifying endoscopy with optical enhancement system
  • Device: white light endoscopy system
N/A

Detailed Description

Stomach cancer is the second most common cause of cancer death. Endoscopic identification and treatment of gastric intestinal metaplasia (GIM) and early gastric cancer (EGC) is essential to improve patients' 5-year survival rates. Conventional endoscopy with white light imaging (WLI) is widely used for endoscopic evaluation of EGCs. However, conventional endoscopic visualization of EGCs has a high rate of interobserver variability and correlates poorly with the histological findings. For this reason, diagnosis has been based mostly on repeated endoscopy with multiple biopsy samples. It has been reported that optical enhancement (OE) system is useful for discriminating cancerous lesions from non-cancerous lesions. The OE system is the newly developed image-enhanced endoscopic technology, which combines high definition white light endoscopy (WLE) and optical filters that limit the spectral characteristics of the illumination light. The optical filters can achieve higher overall transmittance by connecting the peaks of the hemoglobin absorption spectrum creating a continuous wavelength spectrum. Magnifying endoscopy is useful for observing the mucosal structures and microvessels. The VS theory proposed by Yao K is widely used in Magnifying endoscopy with optical enhancement system (ME-OE). Based on technical considerations, it is conceivable that ME-OE imaging techniques might have a distinct advantage over WLE in the diagnosis of endoscopic lesions. However, few reports have objectively proved that ME-OE is superior to WLE in the detection rate and diagnostic efficiency of EGCs.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
300 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Outcomes Assessor)
Primary Purpose:
Diagnostic
Official Title:
Evaluation of the Diagnostic Ability of White Light Endoscopy and Magnifying Endoscopy With Optical Enhancement System in Early Gastric Cancer and Intraepithelial Neoplasia: a Prospective Randomized Controlled Trial
Actual Study Start Date :
May 1, 2020
Anticipated Primary Completion Date :
May 1, 2021
Anticipated Study Completion Date :
May 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: Magnifying endoscopy with optical enhancement system group

Patients in this group go through gastroscopy under the magnifying endoscopy with optical enhancement system.

Device: magnifying endoscopy with optical enhancement system
A complete screening examination was first performed with white light endoscopy. Additionally, the types of endoscopic GIN and EGC were recorded according to the Paris Classification. After visualization in white light mode, the stomach was reinspected by using OE mode2. Then, in vivo diagnoses of lesions were made by using OE mode1 according to VS theory. For all suspicious areas, a minimum of one biopsy specimens were first taken in a targeted fashion.

Active Comparator: white light endoscopy group

Patients in this group go through gastroscopy under white light endoscopy.

Device: white light endoscopy system
A complete screening examination was first performed with white light endoscopy. Additionally, the types of endoscopic GIN and EGC were recorded according to the Paris Classification. For all suspicious areas, a minimum of one biopsy specimens were first taken in a targeted fashion.

Outcome Measures

Primary Outcome Measures

  1. detection rate of GIN and EGC [3 months]

    The primary outcome was the detection rate of gastric intestinal metaplasia (GIM) and early gastric cancer (EGC) in a per-patient analysis.

Secondary Outcome Measures

  1. sensitivity, specificity of diagnostic performances of GIN and EGC [3 months]

  2. positive predictive value of diagnostic performances of GIN and EGC [3 months]

  3. negative predictive value of diagnostic performances of GIN and EGC [3 months]

  4. diagnostic accuracy in a per-biopsy analysis [3 months]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 80 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patients aged 18-80 years with H. pylori infection or histologically verified gastric lesions (chronic atrophic gastritis, intestinal metaplasia, GIN or EGC)

  • Or patients aged 40-80 years from a region with high incidence of gastric cancer

  • Or patients aged 40-80 years with first-degree relative of patients with gastric cancer

  • Or patients aged 40-80 years with high-risk factors for gastric cancer (high salt or pickle diet or smoking or heavy drinking)

Exclusion Criteria:
  • A history of gastrectomy

  • Active gastrointestinal bleeding or advanced gastric carcinoma

  • Coagulopathy or severe underlying diseases

  • Pregnancy or lactation

  • Absence of informed consent

Contacts and Locations

Locations

Site City State Country Postal Code
1 Department of Gastroenterology, Qilu Hospital, Shandong University Jinan Shandong China 250012

Sponsors and Collaborators

  • Shandong University

Investigators

  • Principal Investigator: Yanqing Li, MD, PhD, Shandong University Qilu hosipital, China

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Yanqing Li, doctoral supervisor of Qilu Hospital gastroenterology department, Shandong University
ClinicalTrials.gov Identifier:
NCT04411589
Other Study ID Numbers:
  • 2018SDU-QILU-125
First Posted:
Jun 2, 2020
Last Update Posted:
Sep 25, 2020
Last Verified:
Sep 1, 2020
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Yanqing Li, doctoral supervisor of Qilu Hospital gastroenterology department, Shandong University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 25, 2020